

POCKET GUIDE TO

Parenteral Nutrition

SECOND EDITION

Editor

Pamela Charney

PhD, RD

POCKET GUIDE TO
**Parenteral
Nutrition**
SECOND EDITION

Editor

Pamela Charney

PhD, RD

*Academy of Nutrition and Dietetics
Chicago, IL*

Academy of Nutrition and Dietetics
120 S. Riverside Plaza, Suite 2190
Chicago, IL 60606

Academy of Nutrition and Dietetics Pocket Guide to Parenteral Nutrition, Second Edition

ISBN 978-0-88091-942-5 (print)

ISBN 978-0-88091-943-2 (eBook)

Catalog Number 369X18 (print)

Catalog Number 369X18e (eBook)

Copyright © 2019, Academy of Nutrition and Dietetics. All rights reserved. No part of this publication may be used for commercial exploitation (for example, by resale to others) without the prior written consent of the publisher.

The views expressed in this publication are those of the authors and do not necessarily reflect policies and/or official positions of the Academy of Nutrition and Dietetics. Mention of product names in this publication does not constitute endorsement by the authors or the Academy of Nutrition and Dietetics. The Academy of Nutrition and Dietetics disclaims responsibility for the application of the information contained herein.

10 9 8 7 6 5 4 3 2 1

For more information on the Academy of Nutrition and Dietetics, visit www.eatright.org.

Library of Congress Cataloging-in-Publication Data

Names: Charney, Pamela, 1958- editor. | Academy of Nutrition and Dietetics, issuing body.
Title: Academy of Nutrition and Dietetics pocket guide to parenteral nutrition / [edited by] Pamela Charney.

Other titles: ADA pocket guide to parenteral nutrition. | Pocket guide to parenteral nutrition

Description: Second edition. | Chicago, IL : Academy of Nutrition and Dietetics, [2018]
| Preceded by ADA pocket guide to parenteral nutrition / Pamela Charney and Ainsley
Malone. c2007. | Includes bibliographical references and index.

Identifiers: LCCN 2018023571 (print) | LCCN 2018024417 (ebook) | ISBN 9780880919418
(eBook) | ISBN 9780880919425 (print) | ISBN 9780880919432 (ebook)

Subjects: | MESH: Parenteral Nutrition--methods | Parenteral Nutrition--adverse effects
| Nutrition Assessment | Handbooks

Classification: LCC RM224 (ebook) | LCC RM224 (print) | NLM WB 39 | DDC 615.8/54--dc23
LC record available at <https://lcn.loc.gov/2018023571>

Contents

<i>List of Boxes, Tables, and Figures</i>	v
<i>Frequently Used Terms/Abbreviations</i>	x
<i>Contributors</i>	xiv
<i>Reviewers</i>	xvi
<i>Preface</i>	xviii
<i>Acknowledgments</i>	xx
Chapter 1: The Nutrition Care Process and Evidence-Based Practice	1
Chapter 2: Indications for Parenteral Nutrition in Adults	19
Chapter 3: Vascular Access, Delivery Systems, and Intravenous Pumps	35
Chapter 4: Parenteral Nutrients and Formulations	66
Chapter 5: Initiation, Advancement, and Acute Complications	100
Chapter 6: Metabolic Complications of Long-Term Parenteral Nutrition	131

Chapter 7: Parenteral Nutrition in the Home and Alternate Sites	149
<i>Continuing Professional Education</i>	185
<i>Index</i>	186

SAMPLE
Not for Print
or Resale

List of Boxes, Tables, and Figures

Boxes

Box 2.1 Nutrition Assessment Information Pertinent to Use of Parenteral Nutrition	21
Box 2.2 Examples of Conditions Likely to Require Parenteral Nutrition Across the Life Cycle	25
Box 2.3 Clinical Conditions Warranting Cautious Initiation of Parenteral Nutrition in Adults	29
Box 2.4 Common Indications for Home Parenteral Nutrition	32
Box 3.1 Calculating the Osmolarity of Parenteral Nutrition Solutions	39
Box 3.2 Complications of Vascular Access Device Placement	46
Box 3.3 Complications Associated with Central Catheter Placement	52

Box 3.4 Noninfectious Complications Associated with Vascular Access Devices	55
Box 4.1 Determination of Dextrose Intake Based on Desired Glucose Oxidation Rate	68
Box 4.2 Advantages and Disadvantages of Total Nutrient Admixtures	91
Box 4.3 Examples of Parenteral Nutrition Formulation Prescriptions	94
Box 5.1 Suggested Guidelines for Initial Parenteral Nutrition Prescription	106
Box 5.2 Factors to Consider When Advancing Parenteral Nutrition Volume and Macronutrients	108
Box 5.3 Glycemic Control Subcutaneous Insulin Order Set	114
Box 5.4 Glycemic Control Intensive Intravenous Infusion Order Set	116
Box 5.5 Factors That Place Patients at Risk for Hypertriglyceridemia	118
Box 5.6 Strategies to Limit or Avoid Complications Associated with Intravenous Lipid Emulsion	119
Box 5.7 Factors That Increase Risk for Refeeding Syndrome	120
Box 5.8 Strategies to Prevent and Treat Refeeding Syndrome	122
Box 5.9 Ways to Minimize the Effect of Parenteral Nutrition on Hepatic Function	125

Box 6.1 Potential Etiologies of Parenteral Nutrition–Associated Liver Disease	133
Box 6.2 Macronutrient Suggestions to Reduce Risk of Parenteral Nutrition–Associated Liver Disease	134
Box 6.3 Micronutrients and Non-Nutrient Factors That Can Affect Risk of Developing Parenteral Nutrition–Associated Liver Disease	134
Box 6.4 Reducing the Risk of Complications with Long-Term Parenteral Nutrition	144
Box 7.1 Indications for Home Parenteral Nutrition	152
Box 7.2 Medical Contraindications to Home Parenteral Nutrition	153
Box 7.3 Social Issues That Are Contraindications to Home Parenteral Nutrition	153
Box 7.4 Medicare Reimbursement Criteria for Home Parenteral Nutrition	155
Box 7.5 Information to Complete a Certificate of Medical Necessity for Home Parenteral Nutrition	158
Box 7.6 Discharge Information for Orders and Supplies Provided to the Home Parenteral Nutrition Home-Care Supplier	166
Box 7.7 Self-Monitoring of Fluid Balance	172
Box 7.8 Signs and Symptoms of Metabolic Abnormalities	173
Box 7.9 Patient Guide to Contacting the Home Parenteral Nutrition Clinician	174

Box 7.10 Laboratory Monitoring of Home Parenteral Nutrition	178
Box 7.11 Example of Routine Clinic Follow-Up Schedule for Home Parenteral Nutrition Patients	180

Tables

Table 3.1 Vascular Access Devices Used for Home Parenteral Nutrition	44
Table 4.1 Examples of Crystalline Amino Acid Formulations	69
Table 4.2 Fatty Acid Content of Select 20% Intravenous Lipid Emulsions	74
Table 4.3 Standard Daily Electrolyte Additions to Adult Parenteral Nutrition	77
Table 4.4 Daily Requirements for Adult Parenteral Vitamins	79
Table 4.5 Vitamin Content of Select Commercially Available Products	80
Table 4.6 Daily Trace Element Supplementation in Parenteral Nutrition Formulations in the United States	83
Table 4.7 Examples of Combination Parenteral Trace Element Products for Adults	84
Table 5.1 Recommended Information Needed Prior to Initiating Parenteral Nutrition	103
Table 5.2 Suggested Long-Term Monitoring	104

Table 5.3 Metabolic or Clinical Conditions That Warrant Delay or Cautious Use of Parenteral Nutrition	107
Table 5.4 Insulin Therapy Options During Parenteral Nutrition	112
Table 5.5 Insulin Correctional Scales	115
Table 6.1 Factors That Contribute to Metabolic Bone Disease	137
Table 6.2 General Dosage Recommendations for Specific Nutrients in Long-Term Parenteral Nutrition	141
Table 7.1 Sample Insulin Sliding Scale During Parenteral Nutrition Infusion	163
Table 7.2 Treating High Blood Glucose During Parenteral Nutrition Infusion	164

Figures

Figure 3.1 Vascular access sites for parenteral nutrition	37
Figure 3.2 Catheters for home parenteral nutrition	43
Figure 7.1 Home parenteral nutrition teaching checklist	169
Figure 7.2 Home nutrition support record.....	171

Frequently Used Terms/Abbreviations

- AAC** acute acalculous cholecystitis
- AHRQ** Agency for Healthcare Research and Quality
- AMA** American Medical Association
- ASPEN** American Society for Parenteral and Enteral Nutrition
- ASHP** American Society of Health-System Pharmacists
- AA** amino acid
- AAA** aromatic amino acid
- ACD** automated compounding device
- BMTs** bone marrow transplants
- BCAA** branched chain amino acid

CRBSI	catheter-related blood stream infection
CDC	Centers for Disease Control and Prevention
CMS	Centers for Medicare and Medicaid Services
CVC	central venous catheter
CMN	Certificate of Medical Necessity
CKD	chronic kidney disease
CBC	complete blood count
CII	continuous insulin infusion
D10W	dextrose
DME	direct medical equipment
eNCPT	electronic Nutrition Care Process Terminology
EN	enteral nutrition
EFAD	essential fatty acid deficiency
ESPEN	European Society for Clinical Nutrition and Metabolism
EAL	Evidence Analysis Library
EBP	evidence-based practice
FDA	US Food and Drug Administration

- GI** gastrointestinal
- GIR** glucose infusion rate
- GRADE** Grading of Recommendations, Assessment, Development and Evaluation
- HPN** home parenteral nutrition
- ICU** intensive care unit
- IDPN** intradialytic parenteral nutrition
- IV** intravenous
- IVFE** intravenous fat emulsion
- ILE** intravenous lipid emulsion
- MST** Malnutrition Screening Tool
- MCT** medium chain triglyceride
- MBD** metabolic bone disease
- NPO** nil per os
- NCP** Nutrition Care Process
- NFPE** nutrition-focused physical examination
- NST** nutrition support team
- PN** parenteral nutrition

PNALD	parenteral nutrition–associated liver disease
PICC	peripherally inserted central catheters
PPN	peripheral parenteral nutrition
PES	problem, etiology, and signs and symptoms
POC	point of care
PVC	polyvinyl chloride
RDN	registered dietitian nutritionist
RN	registered nurse
smof	Smoflipid
SCCM	Society of Critical Care Medicine
SQ	subcutaneous
SVC	superior vena cava
TNA	total nutrient admixture
VAD	vascular access device

Contributors

Editor

Pamela Charney, PhD, RD
Associate Professor, University of North Georgia
Dahlonega, GA

Contributors

Therese Berry, MS, RD, LD, CNSC
Nutrition Support Dietitian, Coram CVS/Specialty
Infusion
Solon, OH

Ainsley Malone, MS, RDN, LD, CNSC, FAND, FASPEN
Nutrition Support Team, Mt. Carmel West Hospital
Columbus, OH
Clinical Practice Specialist, The American Society for
Parenteral and Enteral Nutrition
Silver Spring, MD

Mary Marian, DCN, RDN, CSO, FAND
Assistant Professor of Practice
Director, Didactic Program in Dietetics, University of
Arizona
Tucson, AZ

Susan Roberts, MS, RDN, LD, CNSC
Area Director of Clinical Nutrition, Baylor Scott &
White Health
Dietetic Internship Director, Baylor University
Medical Center
Dallas, TX

Reviewers

Mara Lee Beebe, MS, RD, LD, CNSC
Clinical Dietitian, The Ohio State University Wexner
Medical Center
Columbus, OH

Jennifer R. Bridenbaugh, MS, RDN, CNSC
Assistant Professor
Clinical Coordinator, Rutgers School of Health
Professions
Newark, NJ

Mandy L. Corrigan, MPH, RD, CNSC, FAND
Manager, Home Nutrition Support Service for Gut
Rehabilitation and Transplantation, The Cleveland
Clinic
Cleveland, OH

Jennifer Lefton, MS, RDN, CNSC, FAND
Clinical Nutrition Specialist, Medstar Washington
Hospital
Washington, DC

Jay M. Mirtallo, MS, RPh, BCNSP, FASHP, FASPEN
Professor of Clinical Pharmacy
Director, MS in Health System Pharmacy, The Ohio
State University
Columbus, OH

Michelle M. Romano, MS, RDN, CNSC
Manager, Parenteral Nutrition, Clinical Nutrition
Medical Affairs, Fresenius Kabi, USA
Lake Zurich, IL

Laura Williams, MS, RD, LD, CNSC
Registered Dietitian, The Cleveland Clinic
Cleveland, OH

Not for Resale

Preface

The year 2018 marks the 52nd anniversary of the first use of parenteral nutrition (PN) in humans. Since its introduction, thousands of patients have benefited from this life-saving therapy. As members of interdisciplinary healthcare teams caring for patients receiving PN, registered dietitian nutritionists (RDNs) are often responsible for determining the need for PN, ordering nutrient solutions, monitoring patient response to therapy, and coordinating care with patients, caregivers, and other members of the healthcare team.

Since publication of the first edition of the *ADA Pocket Guide to Parenteral Nutrition* in 2007, there have been many changes in how PN is ordered, compounded, and infused. Ten years ago, amino acids were limited to only three or four concentrations, and there was only one lipid solution. Now clinicians can select from multiple amino acid concentrations and several new types of lipid solutions designed to prevent PN associated liver disease. While PN was ordered using paper forms in the past, most now use electronic ordering systems that

have built-in tools that provide information and decision support at the point of care.

Ordering PN remains one of the highest risk activities for even experienced RDNs. As RDNs take responsibility for ordering PN, it is incumbent on them to demonstrate competency to practice in this area.

The text begins with a review of the Nutrition Care Process as it relates to PN and evidence-based practice, proceeds with guidelines for patient selection, and continues through all of the steps required for safe use of PN therapy. In addition to chapters covering ordering, implementation, and monitoring of PN, there are chapters that will be useful for RDNs working in home care and patient education.

This Pocket Guide provides easy-to-understand, step-by-step guidance to serve as a quick reference for RDNs and other members of the nutrition support team. The text is written in a way that will be useful at all levels of practice, including students, novice, and more experienced RDNs.

Acknowledgments

I would be remiss if I did not offer my sincere thanks and appreciation to my coeditor of the first edition of the *ADA Pocket Guide to Parenteral Nutrition*, Ainsley Malone, MS, RD, LD, CNSC, FADA. Without her knowledge and patience, the first edition would not have been possible. Not only did we collaborate on this Pocket Guide, but we also became great friends. I would also like to thank our authors and reviewers, who shared their expertise in making this edition possible, as well as the multidisciplinary team members at Baylor Scott and White Health in Dallas, TX, for their involvement in the development of the order sets adapted for Chapter 5. Additionally, I owe a significant debt of gratitude to the publications staff at the Academy of Nutrition and Dietetics, who shepherded this publication from start to finish!

CHAPTER 1

The Nutrition Care Process and Evidence-Based Practice

The Nutrition Care Process

The Nutrition Care Process (NCP) was developed by the Academy of Nutrition and Dietetics as a mechanism to provide nutrition and dietetics professionals with a framework for critical thinking and decision making in all practice settings.¹ In clinical practice, the NCP serves as a mechanism to ensure that nutrition care is provided for the right patient/client/population, at the right time, by the right professional. The following presents

a review of the NCP, with additional information as it applies to parenteral nutrition.

The objectives of the NCP are¹:

- to provide a standardized process of care
- to support and promote individualized and population care
- to support and encourage use of critical thinking skills, and
- to serve as a structure to validate nutrition care and show that the care provided met the intended purpose.

Nutrition and dietetics terminology published in the electronic Nutrition Care Process Terminology (eNCPT) provides a mechanism to generate qualitative and quantitative data that can be analyzed and interpreted.²

The NCP provides a framework to standardize and facilitate the delivery of nutrition care and serve as the basis to document a rigorous approach to assessment of nutritional status, diagnosis of nutrition problems, determination of appropriate treatment, and evaluation of nutrition care.³ The four steps of the NCP are:

1. Nutrition Assessment
2. Nutrition Diagnosis
3. Nutrition Intervention
4. Nutrition Monitoring and Evaluation

The eNCPT includes standardized terms used to describe each step of the NCP.²

Nutrition Screening

Because nutrition screening may be completed by individuals who are not registered dietitian nutritionists (RDNs), it is considered an entry system and not a step in the NCP.¹ The NCP, however, does rely on screening to identify patients who may have a nutrition diagnosis that would be treated by an appropriate nutrition intervention, including parenteral nutrition (PN). Therefore, accurate nutrition risk screening is a key antecedent activity in the overall process.

The nutrition risk screening process should be designed to quickly and accurately identify patients who may have a nutrition diagnosis or may be at risk for development of nutrition-related complication.

Whenever possible, a validated nutrition risk screen should be utilized. There are several nutrition risk screens that have been validated, including the Malnutrition Screening Tool (MST), which has been recommended for use in acute care settings.^{4,5}

Nutrition Assessment

If risk is identified through the nutrition screening process, a comprehensive nutrition assessment should be performed to diagnose nutrition problems and determine the best mechanism to treat those nutrition diagnoses. While PN can be a life-saving therapy, inappropriate use of PN carries significant risks. Because

PN should only be initiated when the patient cannot or should not consume adequate nutrients via the oral or enteral route, nutrition assessment should include careful evaluation of the gastrointestinal (GI) system along with current nutrient intake.

The NCP provides RDNs with a framework for completing nutrition assessments. A comprehensive nutrition assessment includes evaluation of the following¹:

- food- and nutrition-related history
- anthropometric measurements
- biochemical data, medical tests, and procedures
- nutrition-focused physical findings
- client history

Once all pertinent information is gathered, RDNs are responsible for diagnosing nutrition problems. RDNs utilize critical thinking skills to carefully evaluate and prioritize information that will support the correct nutrition diagnosis. If the RDN does not have reasonable certainty that a nutrition diagnosis is present, additional assessment information must be gathered until there is certainty that there is no nutrition diagnosis or that the correct nutrition problem has been diagnosed.

Nutrition Diagnosis

RDNs are responsible for evaluating information gathered during the nutrition assessment in order to

correctly diagnose nutrition problems. In addition to determining the best intervention to treat the nutrition diagnosis, RDNs must be able to clearly and effectively communicate the nutrition diagnosis to other members of the health care team, patients/clients, and caregivers. Terms from the nutrition diagnosis section of the eNCPT can be used to document nutrition diagnoses in a way that allows other RDNs and health care providers to clearly understand what was diagnosed.²

Many RDNs communicate and document nutrition diagnoses using the PES (problem, etiology, and signs and symptoms) format. A complete review of the PES format is beyond the scope of this guide. Readers are referred to the online eNCPT reference (subscription based; www.ncpro.org) for more information on the nutrition diagnosis statement or PES statement.²

PN is typically initiated in patients who cannot or should not meet their nutrient requirements by oral or enteral nutrition. Nutrition diagnoses that may be associated with the need for PN include (but are not limited to) the following²:

- inadequate energy intake
- inadequate oral intake
- inadequate enteral nutrition infusion
- inadequate protein-energy intake
- altered GI function

Note that Reference Sheets of these and other eNCPT terms provide a full profile of the term that includes a definition, assessment indicators, use examples, and criteria for evaluation.²

Because patients who require PN tend to have very complex health histories, it is not uncommon to see multiple nutrition diagnoses. Identification of all nutrition diagnoses is important. A complete nutrition diagnosis includes the etiology (as part of the PES statement of nutrition diagnosis), which drives the intervention. For example, if the patient has “inadequate energy intake” related to “altered GI function,” the justification of PN as an intervention can be supported.

Nutrition Intervention

Nutrition interventions are actions that RDNs are responsible for taking in order to resolve or improve nutrition diagnoses.¹ Nutrition interventions include actions related to food and nutrient delivery, nutrition education, nutrition counseling, and coordination of care. Identification of the most appropriate nutrition intervention is driven by etiology in the PES statement of the nutrition diagnosis. The intervention must directly focus on alleviating or managing the etiology. For example, if the nutrition diagnosis is “parenteral nutrition composition inconsistent with needs,” and the identified etiology is “excessive dextrose delivery (calculated at 9 mg/kg/min),” the intervention may be

to reduce dextrose delivery rate. If the nutrition diagnosis is an “imbalance of nutrients” related to etiology “insufficient phosphorus to support metabolism of carbohydrate from infusion of PN,” the intervention may be to increase phosphorus provision. Hence, identifying the “why” (etiology) of a nutrition problem is key to provide the optimal “solution” (intervention).

Most of the nutrition interventions directly related to PN fall in the Food and/or Nutrient Delivery Domain, in ND-2 (Enteral and Parenteral Nutrition) of the eNCPT.² Interventions may include the following:

- Initiate PN. (There is no term for initiation of PN; instead, initiation of PN would fall under “Coordination of Nutrition Care by a Nutrition Professional.”)
- Modify the rate, concentration, composition, schedule, and duration of the feeding.
- Provide parenteral nutrition site care.

An exception to this would be the provision of education to patients or caregivers, which would fall under Nutrition Education (E).²

When considering appropriate nutrition interventions, other considerations include end-of-life issues, ethical considerations, patient rights, family/caregiver issues, availability of and access to a qualified practitioner for follow-up and monitoring, and economic constraints that limit the availability of PN.

Monitoring and Evaluation

The monitoring and evaluation step of the NCP offers the clinician the opportunity to review the progress of PN support and to set goals that may include a trial of enteral nutrition (EN) or an oral diet. Monitoring and evaluation must be done at regular intervals, and the RDN must appropriately document progress toward goals set. Monitoring and evaluation should continue until the nutrition diagnosis has been successfully treated or there is a change in the patient's status that requires a change in the intervention.


Evidence for Parenteral Nutrition

Evidence-based practice (EBP) has been defined as “the conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients.”^{6,7}

Guidelines and recommendations have been developed to assist RDNs in determining if there is sufficient evidence to support the use of PN in a given situation.⁸ However, RDNs must evaluate each guideline or recommendation prior to application in clinical practice in order to determine if the guideline applies to the current patient or if the guideline has sufficient strength.

How Are Guidelines Created?

Regulatory agencies and third-party payers may require the use of EBP as a condition for reimbursement. In developing guidelines, clinicians will systematically search the literature for studies to answer clinical questions. However, not all evidence sources and studies are created equal. Systematic reviews of the literature with meta-analysis are considered by most to be the highest level of evidence, while expert review or consensus is considered to be the lowest level of evidence.



From weakest to strongest, the levels of evidence are:

- expert opinion/consensus—weakest
- case study and case-controlled studies
- cohort studies
- randomized controlled trials
- evidence synthesis
- systematic review with meta-analysis—strongest

How to Find Guidelines

Many health care professional organizations provide guidelines that are focused on a given specialty area or answer a specific clinical question. The Academy of Nutrition and Dietetics offers the Evidence Analysis Library (EAL), which is a series of systematic reviews and evidence-based nutrition practice guidelines.^{9,10} Access to the EAL is free for Academy of Nutrition and Dietetics members.

The Agency for Healthcare Research and Quality (AHRQ) sponsors the National Guideline Clearinghouse, a free resource available through the AHRQ website (www.guidelines.gov).¹¹ The website is host to a database containing hundreds of guidelines that can be searched by the clinical condition or by the society that provided the guideline.

The Cochrane Library includes the Cochrane Database of Systematic Reviews, which were created by a dedicated group of volunteers working with an editorial

team. There are over 9,000 systematic reviews included in the Cochrane Library. Each review was created using stringent guidelines for the entire process.¹²

How to Evaluate Guidelines

There are several different questions the practitioner can ask when examining new guidelines, such as:

- Are there clear objectives for the review or guideline?
- Are the methods for the literature search clearly described?
- Are inclusion and exclusion criteria clearly defined?
- Were primary studies evaluated using pre-defined, explicit criteria?
- Was the quality of each study determined?
- Were results reported along with meta-analysis (if appropriate)?
- Were the results interpreted in terms of implications for clinical practice?¹³

Guidelines and Recommendations Related to Parenteral Nutrition

In 2016 the Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral

Nutrition (ASPEN) collaborated on the development of guidelines for the use of nutrition support in critically ill adult patients.⁸ While these guidelines are frequently used as a basis for decision making in patient care, practitioners must remember that the guidelines are based on expert consensus. Although published in 2016, the guidelines do not include studies published after 2013.

The SCCM/ASPEN guidelines utilized the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) process for determining the strength of each recommendation. Using this process of grading, four levels of strength for an individual study can be determined¹⁴:

- High—A great deal of confidence in the results
- Moderate—A chance that the true effect is different from the study results
- Low—Limited confidence in the results
- Very low—Very low confidence in the results

Review of Guidelines

In general, EN rather than PN should be considered when nutrition support is indicated, particularly if the GI tract is even partially functional. The only condition that would be an absolute indication for PN would be when the GI tract is completely nonfunctional. However, when PN is indicated or being considered, RDNs must understand how PN is utilized in different clinical

situations. A review of selected guidelines that discuss which intervention to use—PN or EN—in specific disease states follows.

Oncology

The impact of cancer on nutritional status depends on tumor type, stage, location, and treatment.¹⁵ Many contributing factors, including poor intake, alterations in taste and smell, alterations in intermediary metabolism, and side effects from antineoplastic therapies, are thought to be associated with poor voluntary intake resulting in deterioration in nutritional status. While routine use of PN in patients undergoing cancer treatment is discouraged,^{16,17} there may be some benefit to the use of PN in patients who are receiving bone marrow transplants (BMTs). However, a systematic review found a moderate level of support for the use of EN over PN in patients receiving allogeneic BMT.¹⁸

Critical Illness

Guidelines published in 2016 recommend initiation of PN when it is anticipated that previously well-nourished critically ill patients will not meet their nutritional needs via oral or enteral feeding for more than 7 days, although evidence to support this recommendation was weak.⁸ Additionally, PN should be considered as soon as possible after intensive care unit (ICU) admission for patients

who are already malnourished.⁸ PN should also be considered as a supplement to EN if EN cannot be advanced to at least 60% of caloric goals within 7 to 10 days.⁸

Gastrointestinal Disease

Malnutrition is often associated with GI conditions, such as Crohn's disease and ulcerative colitis, and is generally thought to be caused by malabsorption of macro- and micronutrients. Weight loss, vitamin and mineral deficiencies, and anemia are commonly seen as a result of untreated malnutrition. A recent systematic review stated that PN should only be used in patients with inflammatory bowel disease when EN is not tolerated or feasible.¹⁹

Renal Failure

Acute and chronic renal disease is associated with an increased risk for deterioration in nutritional status due to hypermetabolism, the presence of a chronic inflammatory state, and poor intake related to alterations in taste, nausea, and anorexia. However, EN is always the first therapy of choice for patients with acute or chronic renal failure who are not able to meet their nutrient needs via voluntary oral intake.

Intradialytic parenteral nutrition (IDPN) involves infusing a small volume of PN during hemodialysis. There is little evidence that IDPN is associated with improved nutritional status. Practitioners should

remember that (1) IDPN only supplements other forms of nutrition therapy, (2) IDPN does not increase oral nutrition intake, and (3) IDPN is expensive and may not qualify for reimbursement.²⁰

Peripheral Parenteral Nutrition

Peripheral parenteral nutrition (PPN) is defined as provision of a less concentrated form of PN via a peripheral vein. Most limit PPN to less than 10% final concentration of dextrose and less than 3% final concentration of amino acids. Lipids may or may not be included in PPN. In order for an individual to receive adequate energy, protein, and other nutrients via PPN, a large fluid volume would be required. PPN may be a useful temporary method to provide partial nutrition support in patients with mild to moderate malnutrition until oral or enteral nutrition is resumed or central PN access is obtained. One study showed no difference in outcomes between PPN and standard fluid therapy following colorectal surgery.²¹ PPN tends to be poorly tolerated mainly due to limited suitable peripheral veins that make it difficult and time consuming to maintain access.

Conclusion

PN is considered life-saving therapy for patients who have a nonfunctioning GI tract. Patients with severe intestinal dysfunction, short bowel syndrome,

mechanical bowel obstruction, intractable diarrhea or vomiting, large output fistulas, severe abdominal distention, mesenteric vascular insufficiency, gut ischemia, or infarction are generally the best candidates. Administration of PN is associated with more severe complications and costs than administration of EN. Therefore, EN should be considered as the preferred modality when nutrition support is indicated. The risks and benefits associated with PN must be carefully weighed before support is initiated.

References

1. Swan WI, Vivanti A, Hakel-Smith NA, et al. Nutrition Care Process and model update: toward realizing people-centered care and outcomes management [published online ahead of print October 4, 2017]. *J Acad Nutr Diet*. pii:S2212-2672(17)31117-6. doi:10.1016/j.jand.2017.07.015
1. Academy of Nutrition and Dietetics. Nutrition Terminology Reference Manual (eNCPT): Dietetics Language for Nutrition Care. www.ncpro.org. Accessed September 20, 2017.
2. Hakel-Smith N, Lewis NM. A standardized nutrition care process and language are essential components of a conceptual model to guide and document nutrition care and patient outcomes. *J Am Diet Assoc*. 2004;104(12):1878-1884.
3. Skipper A, Ferguson M, Thompson K, Castellanos V, Porcari J. Nutrition screening tools: an analysis of the evidence. *JPEN J Parenter Enteral Nutr*. 2012;36(3):292-298.
4. Ferguson M, Capra S, Bauer J, Banks M. Development of a valid and reliable malnutrition screening tool for adult acute hospital patients. *Nutrition*. 1999;15(6):458-464.

5. Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB, eds. *Evidence-Based Medicine: How to Practice and Teach EBM*. 2nd ed. Edinburgh, UK: Churchill Livingstone; 2001.
6. Stevens K. The impact of evidence based practice in nursing and the next big ideas. *Online J Issues Nurs*. 2013;18(2):4. doi:10.3912/OJIN.vol18No02Man04.
7. McClave S, Taylor B, Martindale R, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (ASPEN). *JPEN J Parenter Enteral Nutr*. 2016;40(2):159-211.
8. Papoutsakis C, Moloney L, Sinley RC, et al. Academy of Nutrition and Dietetics methodology for developing evidence-based nutrition practice guidelines. *J Acad Nutr Diet*. 2016;117(5):794-804.
9. Academy of Nutrition and Dietetics. Evidence Analysis Library. www.eatrightpro.org/resources/research/applied-practice/evidence-analysis-library. Accessed July 30, 2017.
10. National Guidelines Clearinghouse. Breast cancer screening. www.guideline.gov/summary/summary.aspx?ss=15&doc_id=3990. Accessed January 10, 2008.
11. Cochrane Collaboration. The Cochrane Collaboration: the reliable source of evidence in healthcare. www.cochrane.org. Accessed July 31, 2008.
12. Bigby M. Understanding and evaluating systematic reviews and meta-analysis. *Indian J Dermatol*. 2014;59(2):134-139.
13. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008;336(7650):924-926.

14. Thompson KL, Elliott L, Fuchs-Tarlovsky V, Levin RM, Voss AC, Piemonte T. Oncology evidence-based nutrition practice guideline for adults [published online ahead of print July 16, 2016]. *J Acad Nutr Diet*. 2017;117(2):297-310.e47. doi:10.1016/j.jand.2016.05.010.
15. August D, Huhmann M, ASPEN Board of Directors. ASPEN clinical guidelines: nutrition support during adult anticancer treatment and in hematopoietic cell transplantation. *JPEN J Parenter Enteral Nutr*. 2009;33(5):472-500.
16. Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer. *Clin Nutr*. 2017;36(1):11-48.
17. Baumgartner A, Bargetzi A, Zueger N, et al. Revisiting nutritional support for allogeneic hematologic stem cell transplantation: a systematic review [published online ahead of print January 9, 2017]. *Bone Marrow Transplant*. doi:10.1038/bmt.2016.310.
18. Forbes A, Escher J, Hebuterne X, et al. ESPEN guideline: clinical nutrition in inflammatory bowel disease *Clin Nutr*. 2017; 36(2):321-347. doi:10.1016/j.clnu.2016.12.027.
19. Dukkupati R, Kalantar-Zadeh K, Kopple JD. Is there a role for intradialytic parenteral nutrition? A review of the literature. *Am J Kidney Dis*. 2010;55(2):352-364.
20. Huang H, Wu P, Kang S, et al. Postoperative hypocaloric peripheral parenteral nutrition with branched chain amino acids provides no better clinical advantage than fluid management in nonmalnourished colorectal cancer patients. *Nutr Cancer*. 2014;66(8):1269-1278.

Index

Page numbers followed by *b* indicates box; *f*, figure; *t*, table.

2-in-1 PN formula, 61–62, 90, 94*b*

3-in-1 PN formula, 61–62, 73, 76, 90, 91*b*, 94*b*, 119. *See also* total nutrient admixture (TNA)

AAs. *See* amino acids (AAs)

AAAs. *See* aromatic amino acids (AAA)

AAC. *See* acute acalculous cholecystitis (AAC)

Accreditation Commission for Healthcare, 165

ACDs. *See* automated compounding devices (ACDs)

acetate, 70*t*, 77*t*, 178*b*

acute acalculous cholecystitis (AAC), 123–124

acute respiratory distress syndrome, 74

additives, 78, 85, 86–87, 102

advancement, of parenteral nutrition formulation, 105–108

Agency for Healthcare Research and Quality (AHRQ), 10

AHRQ. *See* Agency for Healthcare Research and Quality (AHRQ)

- air embolism, 47*b*, 53*b*, 55*b*
- alanine, 70*b*
- allergic reactions, 75, 125–126
- aluminum, 85, 137, 140–141, 142*t*
- AMA. *See* American Medical Association (AMA), vitamin requirements of
- American Medical Association (AMA), vitamin requirements of, 78, 139
- American Regent, 84, 94
- American Society for Parenteral and Enteral Nutrition (ASPEN)
 - appropriate use of parenteral nutrition, 23, 71
 - GRADE process, 11–12
 - on aluminum intake
 - on formula calculations, 93
 - on glucose intake, 109
- American Society of Health-System Pharmacists (ASHP), 88
- amino acids (AAs), 69, 69–70*t*, 71–76, 92*b*
 - and bone disease, 137, 137*t*
 - and liver disease, 133*b*
 - and osmolarity, 39*b*
 - crystalline formulations, 69, 69–70*t*
 - dosage recommendations, 141*t*
 - in delivery systems, 61
 - specialized formulas, 66, 71–76, 94*b*
- Aminosyn II solution, 69–70*t*
- anaphylaxis, 125, 126, 139–140
- anemia, 139, 178*b*, 181
- antimicrobial catheters, 60. *See also* catheters

- arginine, 70t
- aromatic amino acids (AAA), 71. *See also* amino acids
- arterial stick, 47b, 53b
- ascorbic acid. *See* vitamin C (ascorbic acid)
- aspartic acid, 70t
- ASHP. *See* American Society of Health-System Pharmacists (ASHP)
- ASPEN. *See* American Society for Parenteral and Enteral Nutrition (ASPEN)
- automated compounding devices (ACDs), 67, 89
- azotemia, 107t
- B Braun Medical Inc, 69–70t, 74t, 94
- bacteria, in vascular access devices, 59, 73
- bacterial resistance, 60
- Baxter International, Inc., 69–70t, 74t, 80–81t, 94
- BCAA. *See* branched chain amino acids (BCAAs)
- biofilm formation, 59–60
- biotin, 79t, 81t
- bisphosphonate therapy, 138
- bone disease, parenteral nutrition–related, 136–138, 137t, 140, 181
- bone marrow transplantation, 13
- bowel obstruction, 32b, 152b
- brachial veins, 39
- branched chain amino acids (BCAAs), 71. *See also* amino acids
- breakage, of catheter, 44t, 47b, 53b, 174
- burns, 123

- calcium, 76, 77t, 78, 137, 141, 141t
- cancer, 13, 120
- Candida* infection, 59
- carbohydrates, 67, 110, 117b, 121, 125b, 134b
- cardiac cachexia, 120b
- carnitine, 86–87, 133b, 140
 - deficiency, 135
- catheter pinch-off, 48b, 54b
- catheter-related bloodstream infection (CRBSI), 46, 58–60
- catheters. *See also* vascular access devices (VADs)
 - antimicrobial, 60
 - care of, 23, 49–51, 174, 174–176b
 - central. *See* central venous catheters
 - complications from, 48b, 52–54b, 55–56b, 57, 58–59, 92b, 135b, 174
 - exit sites, 174
 - implanted, 43t
 - midclavicular, 40
 - midline, 40
 - nontunneled temporary, 38–40, 40–41, 44t, 159
 - patency of, 51
 - peripheral. *See* peripherally inserted central catheters (PICCs)
 - placement of, 30, 37f, 38–42, 47b
 - tunneled, 42, 43t, 44t
- Centers for Medicare and Medicaid Services (CMS), 154
- central parenteral nutrition (CPN)
 - catheter placement for. *See* central venous catheters (CVCs)
 - dextrose concentrations in, 67

- formula osmolarity for, 39, 40*b*
- central venous catheters (CVCs), 30, 44*t*. *See also* catheters
 - complications of, 52–54*b*
 - placement of, 36
- cephalic veins, 38, 39
- Certificate of Medical Necessity (CMN), 157–158
- chemotherapy, 25*b*, 36, 46
- chloride, 70*t*, 77*t*, 107*t*
- cholecystitis. *See* acute acalculous cholecystitis (AAC)
- cholestasis, 124, 135*b*
- choline, 125*b*, 133*b*, 135*b*, 140
- chromium. 83*t*, 84*t*
- chronic kidney disease (CKD), 30
- chylothorax, 46*b*, 53*b*
- CKD. *See* chronic kidney disease (CKD)
- Cleveland Clinic training checklist, 169*f*
- clinic follow-up, 179, 180*b*
- CMN. *See* Certificate of Medical Necessity (CMN)
- CMS. *See* Centers for Medicare and Medicaid Services (CMS)
- Cochran Library, 10–11
- colitis, 14, 25*t*
- Community Health Accreditation Program, 165
- complications
 - of bariatric surgery, 32*b*
 - from fatty acids, 73–74
 - gallbladder, 123–125
 - hepatic. *See* hepatic dysfunction
 - of home parenteral nutrition, 179–180
 - with intravenous lipid emulsions, 119*b*

- infectious, 57, 58
 - of long-term parenteral nutrition, 16, 22–23, 42, 58, 143, 181
 - of peripherally inserted central catheter lines, 48
 - of vascular access devices, 40, 46–48*t*, 49–50, 52, 52–54*b*, 55–56*b*
 - continuous insulin infusion, 110, 112–113*t*. *See also* insulin
- copper, 83*t*, 84*t*, 85, 134*b*, 140
- CPN. *See* central parenteral nutrition (CPN)
- critical illness, 13–14, 118
- CRBSI. *See* catheter-related bloodstream infection (CRBSI)
- Crohn's and Colitis Foundation, 176
- Crohn's disease, 14, 32
- crystalline amino acids, 69, 69–70*t*. *See also* amino acids (AAs)
- CVCs. *See* central venous catheters (CVCs)
- cyanocobalamin. *See* vitamin B-12(cyanocobalamin)
- cyclic infusion, 135*b*
- cysteine, 70*t*
- Dacron velour cuff, 43, 44*t*, 57
- dehydration, 106, 170, 172*b*
- dextrose, 67–68
- and delivery systems, 61, 89–90, 160
 - and hyperglycemia risk, 108*b*, 109–110
 - and liver disease, 133*b*
 - and osmolarity, 6–7, 15, 39*b*, 67–68, 68*b* 94*b*, 141–142*t*
 - and total nutrient admixture stability, 76

- diabetes mellitus, 109–111, 123, 164. *See also* glucose;
hyperglycemia
- diarrhea 16, 25*t*, 160, 170
- dietitian. *See* registered dietitian nutritionist (RDN)
- diphenhydramine, 126
- discharge planning, 151, 165, 166–167*b*
- dislodgment, of catheter, 44–45*t*, 56*b*
- dl-alpha-tocopherol acetate. *See* vitamin E (dl-alpha-tocopherol acetate)
- dressing regimens, for catheter sites, 50, 59
- Durable Medical Equipment Regional Carrier, 154
- dysmotility disorder, 152
- dyspnea, 75, 101, 126
- EAL. *See* Evidence Analysis Library (EAL)
- EBP. *See* evidence-based practice (EBP)
- EFAD. *See* essential fatty acid deficiency (EFAD)
- egg phospholipids, 75, 125–126
- electrolytes, 76–78, 103*t*
- in amino acid formulations, 69, 70*t*
 - imbalances in, 108*b*, 121
 - role in metabolic abnormalities, 172
 - with refeeding syndrome, 122*b*
 - and osmolarity, 39*b*, 69, 77*t*
- enteral nutrition
- transition to, 144*b*, 179
 - vs* parenteral nutrition, 22–23
- Enterococcus* infection, 59
- ergocalciferol. *See* vitamin D (ergocalciferol)
- Escherichia coli* infection, 59

essential fatty acid deficiency (EFAD), 73–75, 118, 141t
ethanol-lock technique, 60
Evidence Analysis Library (EAL), 10
evidence-based practice (EBP), 8–9
exit sites, for catheters, 43, 49, 57

fats. *See* lipids

fatty acids, 72–74, 74t, 133b, 160

femoral veins, 39, 44t

fistulas, 32b, 84, 152b, 160, 170

fluid balance, 103t, 104t, 122b, 172b

fluid overload, 106b, 108b, 170, 172b. *See also*
overhydration

flushing, of catheters, 51, 55b

folic acid, 79t, 81t

Food and Drug Administration. *See* US Food and Drug
Administration (FDA), 78, 88

FreAmine III solution, 69–70t, 94

Fresenius Kabi, 2–73, 74t

gallbladder complications, 123–125

gastrointestinal tract function
and patient selection, 20
and vitamin needs, 84

gauze dressings, 50

glucose

monitoring of, 68, 109, 114b, 116–117b, 162–165
during refeeding syndrome, 121

glucose infusion rate/glucose oxidation rate, 68, 68b

glutamic acid, 70t

- glutamine, 86
 - and hepatic dysfunction, 124, 125*b*
 - for pancreatitis, 133*b*
- glycerol, 73
- glycine, 70
- guidelines, for parenteral nutrition, 8–16

- hand hygiene, 50
- Healthcare Infection Control Practices Advisory Committee, on catheter placement, 40
- hemothorax, 46*b*, 53*b*
- hepatic dysfunction, 118*b*, 124, 125*b*, 135*b*
- hepatic formulas, 71
- histamine 2-receptor antagonists, 87, 135*b*
- histidine, 70*t*
- home parenteral nutrition (HPN)
 - contraindications for, 153*b*
 - complications of, 58–59, 132, 136
 - formula calculation for, 159–160
 - indications for, 31, 32*b*, 152–153, 152*b*
 - infusion schedule for, 160–161, 164
 - Medicare criteria for, 154
 - patient education on, 51–52, 167–168
 - patient resources for, 176–177
 - patient selection for, 150
 - provider selection, 150
 - teaching checklist, 169*f*
 - vascular access device use in, 44–45*t*
- Hospira, 80*t*, 94
- HPN. *See* home parenteral nutrition (HPN)
- hydration, 170, 172*b*, 177

- hydrothorax, 46*b*, 53*b*
hyperbilirubinemia, 86, 124, 134*b*, 140
hypercalciuria, 136, 137*t*
hyperchloremic metabolic acidosis, 107*t*
hyperglycemia, 29*b*, 160*b*, 107*t*, 108*b*, 109–111, 118*b*, 138, 162, 173*b*
hyperkalemia, 173*b*
hypermetabolism, 14
hyponatremia, 29*b*, 107*t*
hyperosmolality, 41, 107*t*
hypertriglyceridemia, 29, 160*b*, 111–119, 118*b*
hypocalcemia, 173*b*
hypochloremic metabolic alkalosis, 107*t*
hypoglycemia, 115*t*, 116*b*, 162, 173*t*
hypokalemia, 107*t*, 121, 173*b*
hypomagnesemia, 29*b*, 107*t*, 121, 173*b*
hypophosphatemia, 29*b*, 107*t*, 121, 173*b*
- IDPN. *See* intradialytic parenteral nutrition (IDPN)
ILE. *See* intravenous lipid emulsion (ILE)
- infection, 57–60
 in the bloodstream, 59–60
 and liver dysfunction, 123, 135*b*
 from vascular access devices, 50, 58
 initiation protocol, 102
- insulin, 87, 110–111, 112–113*t*, 114*b*, 115*t*, 116–117*b*, 121, 162–164, 163*t*
- insurance coverage. *See* Medicare/Medicaid coverage
intestinal ischemia, 16, 33, 123, 152*b*
intestinal transplantation, 136

- intradialytic parenteral nutrition (IDPN), 14–15, 30
- Intralipid, 74*t*
- intravenous fat emulsion (IVFE), 72
- intravenous lipid emulsion (ILE), 72–75, 94*b*, 110, 111, 118–119, 119*b*, 125–126
- iodine, 50
- iron, 83*t*, 139–140, 142*t*, 178*b*
- isoleucine, 69*t*, 71
- IVFE. *See* intravenous fat emulsion (IVFE)
- Joint Commission, 165
- jugular veins, 38–39, 41, 44*t*
- Klebsiella pneumoniae* infection, 59
- laboratory values
- during parenteral nutrition, 177, 178*b*
 - prior to initiating parenteral nutrition, 103*t*
- leucine, 69*t*, 71
- linoleic acid, 72, 74*t*
- linolenic acid, 72, 74*t*
- lipids, 61–62, 72–74, 75, 76, 118, 125*b*, 133, 133*b*, 134*b*, 138–139
- liver disease, *See* parenteral nutrition associated liver disease (PNALD)
- liver dysfunction, 103*t*, 104*t*, 124, 178*b*
- lysine, 69*t*, 86, 135*b*
- macronutrients, 67–70, 105, 106*b*, 108*b*, 125*b*, 133, 138–139. *See also* specific nutrients

- magnesium, 77t, 107t, 121, 137, 139, 178b
- malnutrition, 14, 28, 76–77, 120, 156b
- manganese, 83t, 84–85, 84t, 134b, 140, 142t
- MBD. *See* metabolic bone disease (MBD)
- Medicare/Medicaid coverage, 154–157, 155b, 156b, 157b
- medications, in parenteral nutrition formulations, 87, 108b, 160
- metabolic abnormalities, 172, 173b
- metabolic acidosis, 107t, 137t, 138
- metabolic bone disease (MBD), 136–138, 141t
- methionine, 69t, 86, 135b
- micronutrients, 134b, 135b, 136b, 139–142, 144. *See also* specific nutrients
- midclavicular catheters, 40. *See also* catheters
- midline catheters, 40. *See also* catheters
- monitoring recommendations, during parenteral nutrition, 8, 78, 84, 102, 104t, 109, 160, 162–165, 166b, 170, 177, 178b, 179
- Multitrace solutions, 84
- multivitamin preparations, 78, 125, 139. *See also* vitamins
- MVI solutions, 80t
- NCP. *See* Nutrition Care Process (NCP)
- nerve injury, 48b, 54b
- neurologic impairment, 121, 140
- niacinamide, 80t
- niacin. *See* vitamin B-3 (niacin)
- nitrogen, 69, 69t, 71, 103t, 104t, 122b, 133b, 178b
- nontunneled temporary catheters, 38–40, 40–41, 44t, 159. *See also* catheters

Nutrilipid, 74*t*

NST. *See* nutrition support team (NST)

nutrition assessment, 2, 3–4, 21*b*, 101–102, 156–157*b*, 159, 179

Nutrition Care Process (NCP), 1–8

nutrition diagnosis, 2, 4–6

nutrition intervention, 2, 6–7, 20

nutrition screening, 3

nutrition support team (NST), 149, 150, 166, 176

occlusion, 48*b*, 50, 51, 54*b*, 55–56*b*, 174*b*

octreotide, 160

oil application, topical, 118–119

oleic acid, 74*t*

Oley Foundation, 176

Omegaven, 133

oncology. *See* cancer

osmolarity, 35, 37

calculation of, 38, 39*b*

 formula, 90–93

overhydration, 106*b*, 108*b*, 170, 172*b*. *See also* fluid

 overload

oxalate, 82, 142*t*

palliative care, in parenteral nutrition, 31

palmitic acid, 74*t*

pancreatitis, 26*b*, 32

 triglyceride-induced, 111, 118*b*

pantothenic acid, 79*t*

parenteral nutrition (PN). *See also* home parenteral
 nutrition (HPN)

- advancement of, 105, 106*b*, 107*t*, 108*b*
 - calculation of, 38, 39*b*, 91–93
 - complications of. *See* complications
 - compounding of, 89–94
 - indications for, 8–12, 19–34
 - initiation of, 101–102, 103*t*, 104*t*
 - monitoring during. *See* monitoring
 - recommendations
 - perioperative, 31
 - peripheral. *See* peripheral parenteral nutrition
 - product manufacturers, 74*t*, 80–81*t*, 84*t*, 94
 - schedule for, 160–161
 - toxicity of, 143, 144*b*
 - vs* enteral nutrition, 12–13
- parenteral nutrition associated liver disease (PNALD),
132–133, 133*b*, 134*b*, 135*b*, 136*b*
- patient selection, 51–52, 167–168, 169*f*
- “per day” basis, of formula calculation, 93
- pericardial tamponade, 47*b*, 54*b*
- perioperative parenteral nutrition support, 31
- peripherally inserted central catheters (PICCs), 38, 40,
43*t*, 45*t*, 48–49. *See* also catheters; venous access devices
 - care of, 49–51
 - placement of, 49
- peripheral parenteral nutrition (PPN), 15, 29–30
 - and osmolarity, 90, 93
- pharmacies/pharmacists, 87, 89–90, 91*b*, 151
- phenylalanine, 70*t*, 71
- phlebitis/thromophlebitis, 41
- phosphate, 70*t*, 78, 121
- phosphorus. 29*b*, 76, 77*t*, 107*t*, 137*t*, 140, 141, 142*t*, 178*b*

- phylloquinone. *See* vitamin K (phylloquinone)
- physical assessment, before initiating parenteral nutrition, 20, 21*b*
- physician, role in home parenteral nutrition, 150
- PICCs. *See* peripherally inserted central catheters (PICCs)
- PN. *See* parenteral nutrition (PN)
- PNALD. *See* parenteral nutrition associated liver disease (PNALD)
- pneumothorax, 46*b*, 52*b*
- port-pocket infection, 57
- potassium, 70*t*, 77*t*, 107*t*, 121, 140, 178*b*
- PPN. *See* peripheral parenteral nutrition (PPN)
- product manufacturers, 62, 69, 69*t*, 70*t*, 72, 94, 140
- proline, 70*t*
- propofol, hypertriglyceridemia risk from, 111
- protein, 5, 28, 69, 122*b*, 125*b*, 134*b*, 138
- Pseudomonas* infection, 59
- pyridoxine. *See* vitamin B-6 (pyridoxine)
- radiation enteritis, 32*b*, 152*b*
- real-time content, of aluminum, 140
- refeeding syndrome, 106*b*, 108*b*, 120–122, 120*b*, 122*b*, 153*b*
- refrigeration, for parenteral nutrition solutions, 167
- registered dietitian nutritionist (RDN), role in parenteral nutrition, 4–8, 150
- registered nurse (RN), role in home parenteral nutrition, 150–151
- reimbursement, for home parenteral nutrition, 154–157, 155–157*b*

- renal disease/failure, 14–15, 72, 118*b*, 140
 and vitamin supplementation, 82
- renal formulas, 71–72
- retinol. *See* vitamin A (retinol)
- riboflavin. *See* vitamin B-2 (riboflavin)
- RN. *See* registered nurse (RN), role in home parenteral nutrition
- safflower oil, topical, 72, 75
- SBS. *See* short bowel syndrome (SBS)
- selenium, 82–83, 83*t*, 84*t*
- self-monitoring, during home parenteral nutrition, 170, 172*b*. *See also* monitoring recommendations
- self-sealing septum, 46
- sepsis, 118*b*, 123, 124
- serine, 70*t*
- Serratia marcescens* infection, 59
- Short Bowel Foundation, 177
- short bowel syndrome (SBS), 32*b*, 152*b*, 155*b*
- skin antisepsis, 50, 59
- sliding scale insulin (SSI) protocol, 162, 163*t*. *See also* insulin
- Smoflipid (smof), 72–73, 74*t*, 133
- social worker, role in home parenteral nutrition, 151
- Society for Critical Care Medicine, 11–12
- sodium, 29*b*, 70*t*, 77*t*, 107*t*, 114*b*, 122*b*, 178*b*
- SSI protocol. *See* sliding scale insulin (SSI) protocol
- Staphylococcus* infection, 59
- starvation, physiology of, 120–121. *See also* malnutrition

- stearic acid, 74*t*
- steatosis, 124, 135*b*
- subclavian vein, 38–40, 41
- sunflower oil, topical, 75
- superior vena cava (SVC), catheter tip placement in, 36, 39–40, 41, 49, 56
- SVC. *See* superior vena cava (SVC)

- taurine, 70*t*
- thiamin. *See* vitamin B-1 (thiamin)
- threonine, 70*t*
- thrombophlebitis. *See* phlebitis/thrombophlebitis
- thrombosis, 40, 41, 49, 56*b*
- tissue plasminogen activator, 55
- TNA. *See* total nutrient admixtures (TNA)
- total nutrient admixtures (TNA), 61–62, 73, 76, 90, 91*b*, 94*b*, 119. *See also* 3-in-1 parenteral nutrition formula
- toxicity, of parenteral nutrition, 143, 144*b*
- trace elements, 82–85, 83*t*, 84*t*, 140, 178*b*
- transhepatic veins, 39
- translumbar veins, 39
- transparent dressings, 50
- transplantation, and parenteral nutrition risks, 136
- Travasol solution, 69–70*t*
- triglycerides, 29*b*, 72, 75, 103*t*, 104*t*, 106*b*, 111, 118, 119*b*
- tryptophan, 70*t*, 71
- tunneled catheters, 42, 43*t*, 44*t*. *See also* catheters
- tyrosine, 71

- ulcerative colitis, 14
- ursodeoxycholic acid, 124
- US Food and Drug Administration (FDA), 78, 88

- valine, 70*t*, 71
- vascular access devices (VADs). *See also* catheters
 - anatomical sites for, 36–37, 37*f*
 - care of, 174, 174–176*b*
 - complications of, 46–48*b*, 52, 52–84*b*, 55–56*b*, 179
 - for home parenteral nutrition, 159
 - patient education on, 51–52, 168
 - placement of, 40–41
 - selection of, 36, 150–151
- venous thrombosis. *See* thrombosis
- vitamin A (retinol), 79*t*, 80*t*, 137*t*
- vitamin B-1 (thiamin), 79*t*, 80*t*, 82, 121, 122*b*, 142*t*
- vitamin B-2 (riboflavin), 79*t*, 80*t*
- vitamin B-3 (niacin), 79*t*
- vitamin B-6 (pyridoxine), 79*t*, 80*t*
- vitamin B-12 (cyanocobalamin), 79*t*, 81*t*
- vitamin C (ascorbic acid), 79*t*, 80*t*, 82, 140, 142*t*
- vitamin D (ergocalciferol), 78–79, 79*t*, 80*t*, 136, 137, 137*t*
- vitamin E (dl-alpha-tocopherol acetate), 79*t*, 80*t*
- vitamin K (phyloquinone), 78, 79*t*, 80*t*, 137, 140, 142*t*

- weight monitoring, 102, 104*t*

- zinc, 83–84, 83*t*, 84*t*, 139, 142*t*

POCKET GUIDE TO
Parenteral Nutrition
SECOND EDITION

Written and reviewed by parenteral nutrition experts, this fully updated and evidence-based guide can be used by the nutrition support team in hospitals, long-term care facilities, and home or hospice settings. Topics include:

- indications for parenteral nutrition;
- vascular access, delivery systems, and intravenous pumps;
- parenteral nutrients and formulations;
- initiation, advancement, and acute complications;
- metabolic complications of long-term parenteral nutrition; and
- parenteral nutrition in the home and alternate sites.

An expanded chapter on the Nutrition Care Process addresses nutrition assessment, diagnosis, intervention, and monitoring and evaluation as it applies to the delivery of parenteral nutrition. Appropriate for students to the advanced practitioner, this pocket guide is an indispensable resource.

eat
right. Academy of Nutrition
and Dietetics
CatN 369X18

